KAN-001
Checkpoint Refractory Cancers
Key Facts
About Kanvas Biosciences
Kanvas Biosciences is a private, preclinical-stage biotech leveraging a proprietary spatial mapping technology to illuminate the microbiome and develop next-generation live biotherapeutics. Its vertically integrated platform, spanning from discovery via HiPR-FISH imaging to scalable anaerobic co-culture manufacturing (ACT™), aims to accelerate the development of microbial consortia for diseases like cancer. The company has established a key partnership with MD Anderson Cancer Center and is advancing its lead program, KAN-001, for checkpoint inhibitor-refractory and naïve cancers. Backed by venture capital, including a recent $12.5 million raise, Kanvas is positioning itself at the intersection of advanced imaging, microbiome science, and immuno-oncology.
View full company profileAbout Kanvas Biosciences
Kanvas Biosciences is a private, preclinical-stage biotech leveraging a proprietary spatial mapping technology to illuminate the microbiome and develop next-generation live biotherapeutics. Its vertically integrated platform, spanning from discovery via HiPR-FISH imaging to scalable anaerobic co-culture manufacturing (ACT™), aims to accelerate the development of microbial consortia for diseases like cancer. The company has established a key partnership with MD Anderson Cancer Center and is advancing its lead program, KAN-001, for checkpoint inhibitor-refractory and naïve cancers. Backed by venture capital, including a recent $12.5 million raise, Kanvas is positioning itself at the intersection of advanced imaging, microbiome science, and immuno-oncology.
View full company profile